Stockscreener 앱 받기
7.19
1.51%
-0.11
시간 외 거래:
7.02
-0.17
-2.36%
전일 마감가:
$7.30
열려 있는:
$7.3
하루 거래량:
529.14K
Relative Volume:
0.55
시가총액:
$410.80M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-2.703
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
-5.15%
1개월 성능:
-32.80%
6개월 성능:
+69.58%
1년 성능:
+13.23%
1일 변동 폭
$7.10
$7.37
1주일 범위
$6.96
$7.7099
52주 변동 폭
$2.235
$12.34
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
7.19 | 417.09M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
2026 world cup analysis rankings: Will 4D Molecular Therapeutics Inc. stock gain from strong economy2026 world cup usa national team round of 32 defensive leaders counter attacking winner prediction expert opinion - Улправда
Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock - Investing.com Nigeria
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance
4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion - AD HOC NEWS
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - Улправда
4D Molecular Therapeutics Executive Sells Shares - TradingView — Track All Markets
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha
Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
Is 4D Molecular Therapeutics Inc. stock a top momentum playJuly 2025 Action & Long Hold Capital Preservation Tips - DonanımHaber
Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail
What insider trading reveals about 4D Molecular Therapeutics Inc. stockQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - DonanımHaber
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN) - The Globe and Mail
Stock Market Recap: Is 4D Molecular Therapeutics Inc. stock a top momentum playQuarterly Portfolio Report & Accurate Buy Signal Notifications - DonanımHaber
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Buy” Rating at Chardan Capital - Defense World
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - Nasdaq
What dividend safety score for 4D Molecular Therapeutics Inc. stockJuly 2025 Action & Long-Term Investment Growth Plans - Улправда
4D Molecular Therapeutics : 710 AEROW Interim Phase 1 Data & Program Update (610855) - marketscreener.com
4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha
4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform PotentialSlideshow (NASDAQ:FDMT) 2025-12-17 - Seeking Alpha
4D Molecular Therapeutics Reports Positive Interim Phase 1 Data For 4D-710 In Cystic Fibrosis - Nasdaq
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - Yahoo Finance
Officer Bizily Files To Sell 1,635 Of 4D Molecular Therapeutics Inc [FDMT] - TradingView — Track All Markets
4D Molecular Therapeutics (FDMT) director reports 9,333-share option exercise - Stock Titan
4DMT Announces New Employment Inducement Grants - Sahm
4D Molecular Therapeutics (Nasdaq: FDMT) Issues 13,800 RSUs Under 2025 Inducement Plan - Stock Titan
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
4D Molecular Therapeutics grants CFO option on 480,000 FDMT shares | FDMT SEC FilingForm 4 - Stock Titan
4D Molecular Therapeutics (FDMT) CFO reports no securities holdings - Stock Titan
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - marketscreener.com
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):